⌕
Cg Oncology · CGON · Nasdaq
Tenet 54 · Mixed
Compare
$83.68+12.48%Market openTenet 54 · Mixed
$83.68+9.28 (+12.48%)
Market open · 15-min delayed · as of 10:04 AM ET· Nasdaq · USD

Cg Oncology (CGON) Stock

Cg Oncology (CGON) has a Tenet Score of 54 of 100 against 297 Healthcare peers, as of Nov 13, 2026.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

32 figures withheld by our checks. Each blank figure names its reason.

Key stats

Market cap
$6.6B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
37.01 – 80.97
low → high · as of close, Nov 13, 2026
Tenet Score
54/100
Mixed · 297 Healthcare peers

Industry: Biological Products, Except Diagnostic Substances

Cg Oncology Inc. scores 54/100. Mixed. Strongest on financial health, value is the soft spot versus 297 Healthcare peers. Insufficient inputs: Tenet 54 is built from 3 of 4 pillars, from 40% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=297
54/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
32
Quality
41
Health
89
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueDQualityDHealthBGrowth—MomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
6.7×
price to book value
P/S
1,072.3×
price to fiscal 2025 sales
ROE
−28%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
21.70
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Cg Oncology Inc.

We are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Our product candidate, cretostimogene, is initially in clinical dev…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=297) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 98 US ETFs · top wrappers by weightSee all ETFs holding CGON →

Similar-sized companies in Biological Products, Except Diagnostic Substances

The 1 company in this industry closest in market cap, as of Nov 13, 2026.

CompanyTenet ScoreMarket cap
Inhibrx Biosciences Inc.INBX44$1.2B

What sector and industry is Cg Oncology in?

Cg Oncology is in the Healthcare sector and the Biological Products, Except Diagnostic Substances industry.

What is Cg Oncology's Tenet Score?

Cg Oncology's Tenet Score is 54 out of 100, ranked against 297 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.